TSC2 and neoplasm: TSC2‐ EVs were found to enhance VEGF and HGF secretion from recipient fibroblasts (Figure 5c,d), which we have previously shown to be a feature of a tumour‐supporting fibroblast phenotype (Webber et al., 2015).